StreetAlpha.app
Home › Stocks › AIM

AIM ImmunoTech Inc. (AIM)

$0.14
▼ −0.07%
LAST CLOSE · NOV 17

AIM ImmunoTech develops therapies for cancers, viral diseases and immune disorders, led by its Ampligen treatment candidate. It last closed at $0.14 on Nov 17, down 0.07% on the day.

AI Auto Pilots
Is AIM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$91K
−18.8% vs a year ago
Net income
−$14.1M
−15526.4% margin
EPS (diluted)
−$1.19
Operating margin
−12800.0%
−$11.6M operating income
Valuation
Market cap
$5.4M
39.9M shares
P/E
–
No P/E while losing money
Price to sales
59.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.9M
At Sep 30
Debt
$1.4M
At Sep 30
Shareholder equity
$7.1M
Shares outstanding
39.9M
At Nov 11
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $135K$135KFY2021FY2022: $141K$141KFY2022FY2023: $202K$202KFY2023FY2024: $170K$170KFY2024FY2025: $88K$88KFY2025

From AIM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated AIM in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 5032.0% upside

Based on 1 analyst who set a price target on AIM in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.14.

Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.14
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
Ascendiant CapitalTarget lowered
Aug 20Buy$9 → $7
Ascendiant CapitalMaintained
Jun 1Buy$9
DateFirmActionRatingPrice target
Aug 20Ascendiant CapitalTarget loweredBuy$9 → $7
Jun 1Ascendiant CapitalMaintainedBuy$9
Loading…

Technical Analysis

AIM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 30% below its 50 day average. It is 212% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $0.13, and the nearest resistance the Pivot at $0.14.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.8%/day
Key levels
$1.8852 week high+1242.9%
$0.43200 day average+207.1%
$0.22100 day average+57.1%
$0.1850 day average+28.6%
$0.17Swing high (Oct 28)+21.4%
$0.1620 day average+14.3%
$0.14Pivot R1+0.0%
$0.14Pivot+0.0%
$0.14Last close
$0.13Pivot S1−7.1%
$0.1252 week low−14.3%
$0.12Swing low (Nov 10)−14.3%
Indicators
RSI (14)32.92Weak, oversold below 30Neutral
MACD-0.01Below its signal lineBearish
Stochastic36.1Middle of its rangeNeutral
ADX (14)40.1Strong downtrend
Williams %R-68.8Oversold below −80, overbought above −20Neutral
CCI (20)-154.5Oversold below −100, overbought above 100Oversold
Rate of change−15.6%Change over 10 sessionsBearish
ATR (14)$0.01Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AIM

What happened before

See how AIM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AIM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AIM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AIM in the last 90 days.

Loading…

See today’s whale options flow across the market →

AIM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●7 buying vs 8 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1918+5.6%
In funds' top 1000–
Held by funds2.5%2.9%−0.3 pts
New / increased4 / 34 / 5−22.2%
Reduced / sold out4 / 40 / 4+100.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AIM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AIM is in one of them and how their past AIM trades turned out.

AIM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AIM in an article yet. Here's the latest on the wider market.

About AIM ImmunoTech

AIM ImmunoTech is a biopharmaceutical company based in Ocala, Florida, that develops treatments for cancers, viral diseases and immune disorders. Its lead candidate, Ampligen, is an RNA molecule being studied mainly for pancreatic cancer, with other studies covering viral infections and fatigue after COVID-19. Ampligen is approved for sale in Argentina for severe chronic fatigue syndrome but has not been approved in the United States. The company also offers Alferon N Injection, an interferon product, and aims its therapies at patients with conditions where treatment options are limited.

Headquarters
Ocala, FL